PRE
Prenetics Global Limited
PRE offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
UNH
UnitedHealth Group Incorporated
UNH has a slight edge over PRE overall, supported by lower modeled downside and stronger modeled upside.
PRE Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Weak |
PRE's revenue is currently healthy, but its profitability, cash flow and balance sheet are under pressure.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
PRE PE Valuation
PRE has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
PRE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
PRE has the edge over UNH on the outlook, with more favorable revenue expectations.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
PRE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$4.16 | -$0.29 |
| Q1 2026 | -$4.58 | -$0.77 |
| Q4 2025 | -$4.02 | -$0.31 |
| Q3 2025 | -$3.56 | +$0.26 |
| Q2 2025 | -$3.87 | +$0.27 |
| Q1 2025 | -$3.81 | +$1.51 |
| Q4 2024 | -$3.71 | +$1.90 |
| Q3 2024 | -$3.82 | +$0.24 |
PRE is still losing money, but far less than before: $4.16 per share over the past year, against $96.85 at its worst in mid-2022.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over PRE on earnings quality, reporting a profit while its opponent remains loss making.
PRE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $46.5M | +163% |
| Q1 2026 | $36M | +108% |
| Q4 2025 | $36.6M | +249% |
| Q3 2025 | $23.6M | +203% |
| Q2 2025 | $17.7M | +198% |
| Q1 2025 | $17.3M | +170% |
| Q4 2024 | $10.5M | +99% |
| Q3 2024 | $7.8M | +59% |
PRE has the edge over UNH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -47% | +9.8 points |
| Q1 2026 | -27% | +34 points |
| Q4 2025 | -34% | +124 points |
| Q3 2025 | -26% | +126 points |
| Q2 2025 | -57% | +122 points |
| Q1 2025 | -61% | +81 points |
| Q4 2024 | -158% | +59 points |
| Q3 2024 | -152% | +114 points |
PRE's operating margin was −47% last quarter, up 9.8 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over PRE on profitability, with a higher operating margin.
PRE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $0 | $0 |
| Q1 2026 | -$12.1M | -$12.1M |
| Q4 2025 | -$22M | -$22M |
| Q3 2025 | $0 | $0 |
| Q2 2025 | $0 | $0 |
| Q1 2025 | $0 | $0 |
| Q4 2024 | $0 | $0 |
| Q3 2024 | $0 | $0 |
PRE's free cash flow was −$34M over the past year, against $0 the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over PRE on cash generation, producing positive trailing cash flow while its opponent burns cash.
PRE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.7% | +284K shares |
| 1 year | +30% | +4M shares |
| 3 years | +63% | +6.7M shares |
| 5 years | +561% | +14.7M shares |
PRE has 17M diluted shares, up 30% from a year ago, despite $40M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q2 2026 | $26.9M |
| Q1 2026 | $13.1M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
PRE spent $40M buying back its own shares over the past year, after none the year before.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over PRE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
PRE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2021 | 50.8x | High |
| Q1 2021 | 2.2x | Moderate |
| Q4 2020 | 0.5x | Very low |
PRE's net debt is more than 20 years of its operating earnings (EBITDA).
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
PRE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.2 | Neutral |
| Stochastic | 13.9 | Oversold |
PRE's weekly RSI is 43 (neutral) and its Stochastic is 14 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
PRE PE vs Healthcare Sector
PRE has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
PRE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $18.9 | 12% below |
| 20 week MA | $19.9 | 16% below |
| 50 week MA | $18.8 | 11% below |
| 100 week MA | $13.4 | 24% above |
| 200 week MA | $10.7 | 56% above |
PRE has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 56% above its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over PRE on trend strength, trading above more of its moving averages.
PRE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $120.6 | $31.5 | -74% |
| 2023 | $31.5 | $5.91 | -81% |
| 2024 | $5.91 | $5.70 | -3.6% |
| 2025 | $5.70 | $16.9 | +196% |
| 2026 YTD | $16.9 | $16.7 | -0.9% |
PRE's yearly returns have swung widely, from +196% in 2025 to −81% in 2023. It's down 0.9% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over PRE on returns for 2026, with the stronger performance.